Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment. (April 2018)

• Record Type: Journal Article
• Authors: Thayer, David; Noda, Christopher; Charalel, Resmi; Mills, Abigail; Chang, Randy; Tao, Yu; Akinwande, Olaguoke
• Is Part Of: Journal of comparative effectiveness research. Volume 7:Number 4(2018)
• Page Start: 343
• Page End: 356
• Publication Date: 2018-04
• Subjects: advanced hepatocellular carcinoma -- comparative effectiveness -- hazard ratio -- liver cancer-specific survival -- nonoperative treatment -- overall survival -- palliation -- prognostic prediction; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2017-0064
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: To compare the overall survival (OS) and liver cancer-specific survival of advanced-stage hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with those who received nonoperative/interventional treatment (NOT).Materials & methods: A total of 12, 520 HCC patients from the Surveillance, Epidemiology and End Results database were categorized by treatment with either radioembolization or NOT. Kaplan–Meier and multivariate Cox regression were conducted.Results: The TARE group had both a significantly longer median overall survival than the NOT group (TARE = 9 months; NOT = 2 months; p < 0.0001) and a significantly higher probability of liver cancer-specific survival (hazard ratio = 0.474).Conclusion: TARE appears to provide a significant survival advantage over the NOT population in advanced HCC patients.